Preclinical Study of Ublituximab, a Glycoengineered Anti-Human CD20 Antibody, in Murine Models of Primary Cerebral and Intraocular B-Cell Lymphomas - Concepedia

Concepedia

Publication | Open Access

Preclinical Study of Ublituximab, a Glycoengineered Anti-Human CD20 Antibody, in Murine Models of Primary Cerebral and Intraocular B-Cell Lymphomas

DOI Full Paper Access

35

Citations

19

References

2013

Year

Rym Ben Abdelwahed, Sabrina Donnou, Hanane Ouakrim, Lucile Crozet, Jérémie Cosette, Alexandra Jacquet, Isabel Tourais, Bénédicte Fournès, Mélanie Gillard Bocquet, Amine Miloudi,

Investigative Ophthalmology & Visual Science

Abstract

These in vivo results confirm the potential of the glycoengineered anti-hCD20 mAb ublituximab as an innovative therapeutic approach to treat primary central nervous system lymphoma and other B-cell lymphomas.

References

	Year	Citations

Page 1